Product Description
The global port needle market was valued at $166 million in 2025. This is expected to increase over the forecast period at a CAGR of 1.6% to reach $185 million by 2032.
The full report suite on the global market for port needles includes conventional and safety port needles. The global market for safety port needles encompasses both power-injectable and non-power-injectable variants, featuring built-in mechanisms to prevent needlestick injuries.\
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Port Needle Market Trends
The port needle market has largely transitioned toward safety-engineered devices, reinforcing ASP stability. Ongoing adoption of safety port needles reflects continued emphasis on needlestick injury prevention in clinical settings. Because safety devices command meaningfully higher prices than conventional needles, this sustained conversion is expected to mitigate price erosion and support the overall value of the port needle market throughout the forecast period.
Port Needle Market Share Insights
- Becton Dickinson (BD) held the lead in 2025 in the port needle market, leveraging its substantial safety port needle product portfolio inherited from Bard. This included devices such as Bard® Winged, EZ Huber®, SafeStep® and HuberPlus®. BD’s dominant position in the implantable port market further supported its prominence in the port needle sector, and this dominance is expected to continue throughout the forecast period.
- ICU Medical secured the second position in 2025, with its GRIPPER PLUS® safety port needle constituting a significant portion of its sales. The GRIPPER PLUS® is recognized for its safety, reliability and user-friendliness. It is available as both non-power-injectable and as the GRIPPER PLUS® POWER P.A.C. with power-injection capabilities. ICU Medical’s product range also encompasses GRIPPER® Needles and GRIPPER® Micro Blunt Cannula Non-Coring Safety Needle, the latter featuring the smallest infusion site among available devices. The GRIPPER® Micro Blunt Cannula Needle can be purchased with or without a Y-site and is non-power-injectable.
- Braun occupied the third spot in the market in 2025. Its WHIN® device, introduced in 2010, offers three configurations, including a needle-free injection site model and an open Y-injection site model. Equipped with a safety shield, the WHIN® device provides protection from needlestick injuries and expelled fluids, with a clear housing for easy insertion site visibility. B. Braun’s leading port needle models are those without the Y-site and needleless connector. All its devices are non-power-injectable.
Port Needle Market Segmentation Summary
- Conventional Port Needle Market
- Safety Port Needle Market – Further Segmented Into:
- Device Type: Power-Injectable and Non-Power-Injectable
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
